Singapore IVD Registration and Risk Classification under GN-14 R3

1. Key takeaways

In vitro diagnostic medical devices in Singapore are classified under a separate rule set, GN-14 R3, Guidance on the Risk Classification of In Vitro Diagnostic Medical Devices, updated on 24 July 2023. The classification rules for general medical devices in GN-13 R2.1 cannot be applied to an IVD. The submission format is GN-18 R5 of October 2026, IVD analysers are addressed by dedicated guidance in GN-34 R2 of October 2025 with its Annex 2, and specific segments have their own instruments: dedicated guidance for next generation sequencing and GL-08 R2, the regulatory guidelines for laboratory developed tests of September 2025.

• Classification follows GN-14 R3, not GN-13 R2.1. Using the general device logic is the most common technical error in IVD filings.
• Dossier format follows GN-18 R5, the IVD revision of the ASEAN CSDT guidance, dated October 2026 and paired with the IVD electronic submission guide R5.
• Reagents and analysers are assessed under different instruments: GN-34 R2 with Annex 2 covers IVD analysers and supplies a structured template.
• Grouping for IVDs is built around platform, detection principle and analyte family rather than around structural continuity.
• Laboratory developed tests follow GL-08 R2 of September 2025 with its Annex 1 target list template, not the commercial IVD registration route.

2. Legal basis

GN-14 R3 governs risk classification for IVD medical devices and was updated on 24 July 2023. The parallel instrument for general devices is GN-13 R2.1, published on 18 September 2025, and the two are deliberately separate: an IVD is classified on the basis of its diagnostic purpose, its target analyte, its setting of use and the risk attached to an erroneous result, not on the basis of invasiveness or duration of contact. Submission content is set by GN-18 R5 of October 2026, and the electronic filing route is the E-Submission Guide for IVD MD in MEDICS R5 of the same month.

The reason the two classification systems must be kept apart is structural rather than stylistic. A general device is classified by the risk its physical intervention presents to the patient. An IVD does not intervene physically at all; the risk it carries is the risk of a wrong result and what that wrong result causes downstream. The further consequence is that a single IVD product family can straddle several classes depending on the analyte and the claimed use, which makes the classification record the first document to settle and the last to change. Regulatory information in this article was verified to 26 October 2026 against secondary sources, namely GN-14 R3, GN-18 R5, GN-34 R2, GL-08 R2 and GN-12-1 R3.

3. Expert insights

IVDs and general devices are two parallel rule sets, and mixing them is the most common technical error. Many clients arrive with a classification rationale copied from a general device file, and the result is a wrong class, a wrong route and a wrong fee. The IVD logic rests on the purpose of the test, the target analyte, the setting in which it is used and the consequence of an erroneous result. None of those factors appear in the invasiveness and duration framework applied to general devices, so a rationale built on that framework answers a question nobody asked.

Reagents and analysers are handled separately but can be planned together. GN-34 R2 deals specifically with IVD analysers, and its Annex 2 provides a structured checklist template that replaces free-form description. For a product line that includes both reagents and an instrument, our practice is to determine classification and route separately for each, then assess whether a combined submission or a grouping under GN-12 is available. Doing it in that order avoids the situation where two rule sets collide only at the point of filing, when the dossier is already written.

IVD grouping follows platform, principle and analyte family. Grouping for general devices often turns on continuity of structure and materials. IVD grouping does not. It is usually organised around a shared detection principle, a shared analyte family and a shared platform, because those are the variables that determine whether performance evidence for one member can support another. Applying the general device continuity logic to an IVD produces a grouping that a reviewer will dismantle, and the dismantling usually arrives as a request for additional performance data.

Laboratory developed tests have a dedicated route and a different regulatory logic. GL-08 R2 of September 2025 governs laboratory developed tests and provides the Annex 1 target list template. A client operating an LDT service needs to work through that instrument rather than through the commercial IVD product registration route. The distinction is not merely procedural: the two frameworks ask different questions about the test, its validation and the laboratory that runs it, so a dossier prepared on the commercial IVD model does not answer the LDT questions.

A Class A IVD still goes through product notification and does not enter the SMDR. This matches the treatment of other Class A devices. Product registration is waived, but the product must be notified and the company must hold a dealer’s licence. The notification is not a registration by another name, and treating it as an optional step is a common error for low-risk IVDs such as general laboratory reagents, where the commercial team may assume that nothing needs to be filed at all.

4. Practical recommendations

• Classify every IVD under GN-14 R3 and record the reasoning, rather than adapting a classification note written for a general device.
• Determine classification and route separately for reagents and for analysers, then decide on a combined submission or a grouping.
• Prepare analyser content against GN-34 R2 using the Annex 2 template, which provides the structure the reviewer expects.
• Design the grouping strategy on IVD logic, built around platform, principle and analyte family.
• Route LDT business through GL-08 R2 with the Annex 1 template, and do not force it into the commercial IVD framework.

5. Verification checklist

• □ IVD classification determined under GN-14 R3, not GN-13.
• □ GN-18 R5 confirmed as the applicable submission format.
• □ Reagents and analysers classified separately.
• □ Analyser documentation prepared to GN-34 R2 and Annex 2.
• □ Grouping strategy designed on IVD logic.
• □ LDT activity routed through GL-08 R2.
• □ Class A IVD notified as a product, with a dealer’s licence held.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Singapore. Our team prepares dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with HSA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com